Multitarget therapy versus monotherapy as induction treatment for lupus nephritis: A meta-analysis of randomized controlled trials
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Young Ho | - |
dc.contributor.author | Song, Gwan Gyu | - |
dc.date.accessioned | 2022-11-17T22:40:40Z | - |
dc.date.available | 2022-11-17T22:40:40Z | - |
dc.date.created | 2022-11-17 | - |
dc.date.issued | 2022-10 | - |
dc.identifier.issn | 0961-2033 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/145687 | - |
dc.description.abstract | Aim The safety of multitarget treatments is of concern. This study aimed to evaluate the effectiveness and safety of multitarget therapy as an induction treatment for lupus nephritis in comparison with monotherapy. Methods This study included randomized controlled trials (RCTs) that evaluated the effectiveness and safety of multitarget therapies, such as voclosporin+mycophenolate mofetil (MMF), tacrolimus+MMF, or belimumab+standard of care in comparison with MMF or cyclophosphamide (CYC) monotherapy for induction treatment of lupus nephritis. We performed a meta-analysis of the efficacy and safety of multitarget therapy as an induction treatment for lupus nephritis in comparison with monotherapy Results Six RCTs, including 1,437 participants, met the inclusion criteria. The complete remission rate was significantly higher in the multitarget therapy group than in the monotherapy group (odds ratio, 2.155; 95% CI, 1.695-2.739; p < 0.001). Subgroup analysis revealed that the complete remission rate was significantly higher in both tacrolimus+MMF and voclosporin+MMF groups as well as the belimumab+standard of care (SOC) than in the monotherapy or SOC group. The incidence of adverse events did not differ between the multitarget therapy and monotherapy groups. However, cases of infection and pneumonia were numerically higher in the multitarget therapy group than in the monotherapy group. In addition, the incidence of menstrual disorder was significantly lower in the tacrolimus+MMF group than in the CYC group, whereas that of new-onset hypertension was considerably higher in the tacrolimus+MMF group than in the CYC group. Conclusions Multitarget therapy showed a higher complete remission rate than monotherapy; however, cases of infection and pneumonia were numerically more elevated in the multitarget therapy group than in the monotherapy group. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | SAGE PUBLICATIONS LTD | - |
dc.subject | MYCOPHENOLATE-MOFETIL | - |
dc.subject | CYCLOPHOSPHAMIDE | - |
dc.subject | ERYTHEMATOSUS | - |
dc.title | Multitarget therapy versus monotherapy as induction treatment for lupus nephritis: A meta-analysis of randomized controlled trials | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Lee, Young Ho | - |
dc.identifier.doi | 10.1177/09612033221122148 | - |
dc.identifier.scopusid | 2-s2.0-85136595469 | - |
dc.identifier.wosid | 000842128500001 | - |
dc.identifier.bibliographicCitation | LUPUS, v.31, no.12, pp.1468 - 1476 | - |
dc.relation.isPartOf | LUPUS | - |
dc.citation.title | LUPUS | - |
dc.citation.volume | 31 | - |
dc.citation.number | 12 | - |
dc.citation.startPage | 1468 | - |
dc.citation.endPage | 1476 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Rheumatology | - |
dc.relation.journalWebOfScienceCategory | Rheumatology | - |
dc.subject.keywordPlus | MYCOPHENOLATE-MOFETIL | - |
dc.subject.keywordPlus | CYCLOPHOSPHAMIDE | - |
dc.subject.keywordPlus | ERYTHEMATOSUS | - |
dc.subject.keywordAuthor | Tacrolimus | - |
dc.subject.keywordAuthor | voclosporin | - |
dc.subject.keywordAuthor | multitarget therapy | - |
dc.subject.keywordAuthor | lupus nephritis | - |
dc.subject.keywordAuthor | meta-analysis | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.